Literature DB >> 26067607

Ubiquitin-protein ligase E3C promotes glioma progression by mediating the ubiquitination and degrading of Annexin A7.

Si-Jian Pan1, Shi-Kun Zhan2, Wei-Zhong Ji3, Yi-Xin Pan2, Wei Liu2, Dian-You Li2, Peng Huang2, Xiao-Xiao Zhang2, Chun-Yan Cao2, Jing Zhang2, Liu-Guan Bian1, Bomin Sun2, Qing-Fang Sun1.   

Abstract

The ubiquitin-protein ligase E3C (UBE3C) belongs to the E3 ligase enzyme family and implicates in the ubiquitin-proteasome pathway, thus regulates physiological and cancer-related processes. Here, we investigated the expression and roles of UBE3C in glioma. We demonstrated that UBE3C was overexpressed in glioma tissues and cell lines. Inhibition of UBE3C expression in glioma cells significantly decreased cell migration and invasion in vitro. Mechanistically, we disclosed that UBE3C physically interacted with and ubiquitinated tumor suppressor gene annexin A7 (ANXA7), resulting in ubiquitination and degradation of ANXA7. Our results also revealed that increased UBE3C expression was accompanied by a reduction in ANXA7 protein expression in glioma tissues, but not ANXA7 mRNA. Importantly, the inhibition of ANXA7 expression in gliomas cells with UBE3C interference could rescue the cell invasion. Clinically, UBE3C overexpression significantly correlated with high-grade tumors (p < 0.05), poor overall survival, and early tumor recurrence. Thus, our data reveal that high UBE3C expression contributes to glioma progression by ubiquitination and degradation of ANXA7, and thus presents a novel and promising target for glioma therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26067607      PMCID: PMC4464076          DOI: 10.1038/srep11066

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  33 in total

1.  The E3 ubiquitin ligase UBE3C enhances proteasome processivity by ubiquitinating partially proteolyzed substrates.

Authors:  Bernard W Chu; Kyle M Kovary; Johan Guillaume; Ling-chun Chen; Mary N Teruel; Thomas J Wandless
Journal:  J Biol Chem       Date:  2013-10-24       Impact factor: 5.157

2.  Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.

Authors:  Antonio Sacco; Monette Aujay; Brittany Morgan; Abdel Kareem Azab; Patricia Maiso; Yang Liu; Yong Zhang; Feda Azab; Hai T Ngo; Ghayas C Issa; Phong Quang; Aldo M Roccaro; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2011-02-25       Impact factor: 12.531

Review 3.  Characterizing DNA methylation alterations from The Cancer Genome Atlas.

Authors:  Daniel J Weisenberger
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

4.  The ubiquitin E3 ligase RAUL negatively regulates type i interferon through ubiquitination of the transcription factors IRF7 and IRF3.

Authors:  Yanxing Yu; Gary S Hayward
Journal:  Immunity       Date:  2010-12-14       Impact factor: 31.745

5.  ANXA7, PPP3CB, DNAJC9, and ZMYND17 genes at chromosome 10q22 associated with the subgroup of schizophrenia with deficits in attention and executive function.

Authors:  Chih-Min Liu; Cathy S-J Fann; Chien-Yu Chen; Yu-Li Liu; Yen-Jen Oyang; Wei-Chih Yang; Chien-Ching Chang; Chun-Chiang Wen; Wei J Chen; Tzung-Jeng Hwang; Ming H Hsieh; Chen-Chung Liu; Stephen V Faraone; Ming T Tsuang; Hai-Gwo Hwu
Journal:  Biol Psychiatry       Date:  2011-04-30       Impact factor: 13.382

6.  M phase phosphorylation of the epigenetic regulator UHRF1 regulates its physical association with the deubiquitylase USP7 and stability.

Authors:  Honghui Ma; Hao Chen; Xue Guo; Zhentian Wang; Mathew E Sowa; Lijuan Zheng; Shibin Hu; Pingyao Zeng; Rui Guo; Jianbo Diao; Fei Lan; J Wade Harper; Yujiang Geno Shi; Yanhui Xu; Yang Shi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-12       Impact factor: 11.205

7.  αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma.

Authors:  Xiao-Yong Huang; Ai-Wu Ke; Guo-Ming Shi; Xin Zhang; Chi Zhang; Ying-Hong Shi; Xiao-Ying Wang; Zhen-Bin Ding; Yong-Sheng Xiao; Jun Yan; Shuang-Jian Qiu; Jia Fan; Jian Zhou
Journal:  Hepatology       Date:  2013-05-14       Impact factor: 17.425

8.  Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.

Authors:  Lale Erdem-Eraslan; Lonneke A Gravendeel; Johan de Rooi; Paul H C Eilers; Ahmed Idbaih; Wim G M Spliet; Wilfred F A den Dunnen; Johannes L Teepen; Pieter Wesseling; Peter A E Sillevis Smitt; Johan M Kros; Thierry Gorlia; Martin J van den Bent; Pim J French
Journal:  J Clin Oncol       Date:  2012-12-26       Impact factor: 44.544

Review 9.  Potential role of annexin A7 in cancers.

Authors:  Chunmei Guo; Shuqing Liu; Frederick Greenaway; Ming-Zhong Sun
Journal:  Clin Chim Acta       Date:  2013-04-29       Impact factor: 3.786

10.  Profiling of the tetraspanin CD151 web and conspiracy of CD151/integrin β1 complex in the progression of hepatocellular carcinoma.

Authors:  Ranjan Prasad Devbhandari; Guo-Ming Shi; Ai-Wu Ke; Fei-Zhen Wu; Xiao-Yong Huang; Xiao-Ying Wang; Ying-Hong Shi; Zhen-Bin Ding; Yang Xu; Zhi Dai; Jia Fan; Jian Zhou
Journal:  PLoS One       Date:  2011-09-22       Impact factor: 3.240

View more
  13 in total

1.  Multicellular biomarkers of drug resistance as promising targets for glioma precision medicine and predictors of patient survival.

Authors:  Yuting Lu; Yongzhao Shao
Journal:  Cancer Drug Resist       Date:  2022-06-02

2.  Urinary biomarker discovery in gliomas using mass spectrometry-based clinical proteomics.

Authors:  Jianqiang Wu; Jun Zhang; Jing Wei; Yuanli Zhao; Youhe Gao
Journal:  Chin Neurosurg J       Date:  2020-04-14

Review 3.  The Role of the Ubiquitin Proteasome System in Glioma: Analysis Emphasizing the Main Molecular Players and Therapeutic Strategies Identified in Glioblastoma Multiforme.

Authors:  Semer Maksoud
Journal:  Mol Neurobiol       Date:  2021-03-04       Impact factor: 5.682

4.  GSK621 Targets Glioma Cells via Activating AMP-Activated Protein Kinase Signalings.

Authors:  Hong Jiang; Wei Liu; Shi-Kun Zhan; Yi-Xin Pan; Liu-Guan Bian; Bomin Sun; Qing-Fang Sun; Si-Jian Pan
Journal:  PLoS One       Date:  2016-08-17       Impact factor: 3.240

5.  Ubiquitin ligase UBE3C promotes melanoma progression by increasing epithelial-mesenchymal transition in melanoma cells.

Authors:  Li Tang; Xue-Mei Yi; Jia Chen; Fu-Juan Chen; Wei Lou; Yun-Lu Gao; Jing Zhou; Li-Na Su; Xin Xu; Jia-Qing Lu; Jun Ma; Ning Yu; Yang-Feng Ding
Journal:  Oncotarget       Date:  2016-03-29

6.  Activity-Based Probes for HECT E3 Ubiquitin Ligases.

Authors:  Robert Byrne; Thomas Mund; Julien D F Licchesi
Journal:  Chembiochem       Date:  2017-06-28       Impact factor: 3.164

7.  Post-translational modifications of FDA-approved plasma biomarkers in glioblastoma samples.

Authors:  Natalia A Petushkova; Victor G Zgoda; Mikhail A Pyatnitskiy; Olesya V Larina; Nadezhda B Teryaeva; Alexander A Potapov; Andrey V Lisitsa
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

8.  Lnc-THOR silencing inhibits human glioma cell survival by activating MAGEA6-AMPK signaling.

Authors:  Jun Xue; Shan Zhong; Bo-Min Sun; Qing-Fang Sun; Liang-Yun Hu; Si-Jian Pan
Journal:  Cell Death Dis       Date:  2019-11-14       Impact factor: 8.469

Review 9.  Molecular Evolution, Neurodevelopmental Roles and Clinical Significance of HECT-Type UBE3 E3 Ubiquitin Ligases.

Authors:  Mateusz C Ambrozkiewicz; Katherine J Cuthill; Dermot Harnett; Hiroshi Kawabe; Victor Tarabykin
Journal:  Cells       Date:  2020-11-10       Impact factor: 6.600

10.  Cul4A Modulates Invasion and Metastasis of Lung Cancer Through Regulation of ANXA10.

Authors:  Ming-Szu Hung; Yi-Chuan Chen; PaulYann Lin; Ya-Chin Li; Chia-Chen Hsu; Jr-Hau Lung; Liang You; Zhidong Xu; Jian-Hua Mao; David M Jablons; Cheng-Ta Yang
Journal:  Cancers (Basel)       Date:  2019-05-02       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.